Background No therapeutics have yet been proven effective for the treatment of severe
illness caused by SARS-CoV-2. Methods We conducted a randomized, controlled, open-label …

Background No specific antiviral drug has been proven effective for treatment of patients
with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside …

A clinical prediction model is a tool for predicting healthcare outcomes, usually within a
specific population and context. A common approach is to develop a new clinical prediction …

Background Tocilizumab is a monoclonal antibody that binds to the receptor for interleukin (IL)-6,
reducing inflammation, and is commonly used to treat rheumatoid arthritis. We …

Adaptive designs can make clinical trials more flexible by utilising results accumulating in
the trial to modify the trial’s course in accordance with pre-specified rules. Trials with an …

Background: Endpoint choice for randomized controlled trials of treatments for novel
coronavirus-induced disease (COVID-19) is complex. Trials must start rapidly to identify treatments …

We generalize the Dunnett test to derive efficacy and futility boundaries for a flexible multi-arm
multi-stage clinical trial for a normally distributed endpoint with known variance. We show …

Responding to Global Infectious Disease Outbreaks As in the ongoing Covid-19 pandemic,
global outbreaks of infectious illnesses often develop quickly and resolve in unpredictable …

Background Coronavirus disease 2019 (COVID-19) is associated with diffuse lung damage.
Corticosteroids may modulate immune-mediated lung injury and reducing progression to …

Background Lopinavir–ritonavir has been proposed as a treatment for COVID-19 on the basis
of in vitro activity, preclinical studies, and observational studies. Here, we report the results …